The patient was a 78-year-old woman who suffered from right upper quadrant pain. She was diagnosed as colon cancer with hepatic metastasis. Initial chemotherapy using capecitabine plus oxaliplatin (XELOX)+bevacizumab achieved partial response. After 12 months, XELOX was discontinued due to Grade 3 hand-foot syndrome and peripheral neuropathy. Irinotecan plus oral S-1 (a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate) and (IRIS)+bevacizumab were continued as second-line therapy, and her status was maintained as stable disease. XELOX and IRIS regimens do not require catheter placement and long infusion process, providing a great advantage to patients.
|ジャーナル||Japanese Journal of Cancer and Chemotherapy|
|出版ステータス||Published - 2013 6月|
ASJC Scopus subject areas